Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Zymeworks Inc., Kymera Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Zymeworks Inc., Kymera Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Zymeworks Inc., Kymera Therapeutics and Inc.
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Latest Biotechnology and Zymeworks Inc., Kymera Therapeutics, Inc. Stock News
As of November 26, 2025, Zymeworks Inc. had a $2.0 billion market capitalization, compared to the Biotechnology median of $220.1 million. Zymeworks Inc.’s stock is up 86.7% in 2025, up 20.9% in the previous five trading days and up 91.25% in the past year.
Currently, Zymeworks Inc. does not have a price-earnings ratio. Zymeworks Inc.’s trailing 12-month revenue is $134.5 million with a -47.2% net profit margin. Year-over-year quarterly sales growth most recently was 72.5%. Analysts expect adjusted earnings to reach $-0.873 per share for the current fiscal year. Zymeworks Inc. does not currently pay a dividend.
As of November 26, 2025, Kymera Therapeutics, Inc. had a $4.9 billion market cap, putting it in the 69th percentile of all stocks. Kymera Therapeutics, Inc.’s stock is up 68.7% in 2025, up 4.7% in the previous five trading days and up 50.87% in the past year.
Currently, Kymera Therapeutics, Inc. does not have a price-earnings ratio. Kymera Therapeutics, Inc.’s trailing 12-month revenue is $43.7 million with a -674.8% net profit margin. Year-over-year quarterly sales growth most recently was -24.3%. Analysts expect adjusted earnings to reach $-3.477 per share for the current fiscal year. Kymera Therapeutics, Inc. does not currently pay a dividend.
How We Compare Zymeworks Inc., Kymera Therapeutics and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Zymeworks Inc., Kymera Therapeutics and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions